Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873356 | 0.83 | TDO2 (0.31) | BRD4 | |
| SCHEMBL17873389 | 0.77 | JAK2 (0.46) | BRAF | |
| SCHEMBL17873424 | 0.77 | PTPN11 (0.33) | MEN1LMNAPABPC1KMT2A | |
| SCHEMBL19701202 | 0.76 | — | — | |
| SCHEMBL17883468 | 0.74 | LRRK2 (0.34) | — | |
| SCHEMBL19273386 | 0.73 | KCNMA1 (0.41) | — | |
| SCHEMBL17873392 | 0.71 | CTSS (0.36) | — | |
| SCHEMBL17873411 | 0.70 | CTSS (0.39) | — | |
| SCHEMBL17873336 | 0.70 | CSNK2A1 (0.47) | LMNABRD4 | |
| SCHEMBL19710083 | 0.67 | GPR84 (0.40) | MEN1LMNAPABPC1KMT2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2025-06-26 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3237419-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3237419-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397798-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2020-12-24 | — | — | US | disclosed |
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2019-07-11 | — | — | US | disclosed |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017205684-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2017-11-30 | — | — | WO | disclosed |
| EP-3237419-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Akarna Therapeutics, Ltd. (GB) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016103037-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016103037-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | MEN1 285/4885LMNA 450/4885PABPC1 2845/4885 |
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | MEN1 285/4885LMNA 450/4885PABPC1 2845/4885 |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | MEN1 285/4885LMNA 450/4885PABPC1 2845/4885 |
| US-20200397798-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | DPP4, TLR1, SLC5A1 | MEN1 4466/4885LMNA 4336/4885PABPC1 3780/4885 |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | MEN1 285/4885LMNA 450/4885PABPC1 2845/4885 |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | MEN1 285/4885LMNA 450/4885PABPC1 2845/4885 |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | MEN1 285/4885LMNA 450/4885PABPC1 2845/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | MEN1 285/4885LMNA 450/4885PABPC1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.